MAPREG has a total of 15 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2003. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals are ALLAYSIS LLC, OBEN JULIUS ENYOUG and REIG JOFRE S A LAB.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 5 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | WIPO (World Intellectual Property Organization) | 3 | |
#4 | Australia | 1 | |
#5 | Canada | 1 | |
#6 | France | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Villey Isabelle | 8 |
#2 | Baulieu Etienne | 8 |
#3 | Fellous Esther | 6 |
#4 | Robel Paul | 6 |
#5 | George Olivier | 5 |
#6 | Jean Mason Barbara | 5 |
#7 | Baulieu Etienne-Emile | 5 |
#8 | Koob George F | 5 |
#9 | Bianchi Massimiliano | 3 |
#10 | Baulieu Etienne Emile | 1 |
Publication | Filing date | Title |
---|---|---|
US2017252358A1 | Non-bioconvertible C3-substituted pregnenolone derivatives for use in the treatment of treatment-resistant depression | |
EP3436024A1 | Non-bioconvertible c3-substituted pregnenolone derivatives for use in the treatment of treatment-resistant depression | |
EP3165225A1 | Non-bioconvertible c3-substituted pregnenolone derivatives for use in the treatment of substance use disorders | |
US2013244991A1 | Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury | |
FR2850023A1 | DRUGS FOR THE NERVOUS SYSTEM |